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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is
tanezumab more effective than a placebo in reducing pain in patients with osteoarthritis?”
STUDY DESIGN: Review of three randomized, double-blind, placebo controlled trials from
2012 to 2015.
DATA SOURCES: Three double-blind randomized clinical trials (RCTs) were found using
PubMed, and selected based on outcomes measured and relevance to the objective.
OUTCOMES MEASURED: Clinical outcomes of knee and hip osteoarthritis pain were
measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
pain scale to assess pain before and after treatment with tanezumab and comparison.
RESULTS: All three randomized studies showed treatment with tanezumab was statistically
significant (p-value ≤0.001) for improvement in pain at 16 weeks after injections. An adverse
event was reported in each study.
CONCLUSIONS: Based on the studies reviewed in this paper, the evidence suggest the efficacy
of tanezumab for hip and knee osteoarthritis pain is conclusive as an effective treatment.
KEY WORDS: Osteoarthritis, tanezumab, knee pain, hip pain
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INTRODUCTION
Osteoarthritis (OA) is the most common form of arthritis, affecting millions of people
worldwide. OA is a slowly progressive joint disease typically seen in middle-age to elderly
individuals.1 It causes debilitating pain and can lead to a loss of function in mobility, which
eventually decreases an individual’s quality of life. OA is characterized by the breakdown of
cartilage on the ends of bones, bony changes to the joints, deterioration of tendons and ligaments,
and various degrees of inflammation of the joint lining.1 At least 15 percent of all adults over the
age of 60 are believed to suffer from this disorder with females having greater prevalence of
osteoarthritis than males.2 While the definitive treatment for OA is total joint replacement,
patients seek less invasive forms of treatment to relieve their pain, improve their function, and
prolong their quality of life. This paper evaluates three randomized controlled trials (RCTs)
comparing the efficacy of tanezumab as an oral medication for reducing pain in patients with
osteoarthritis.
Osteoarthritis ranks fifth among all forms of disability worldwide.2 Hip and knee
osteoarthritis represent a significant cause of that disability.2 Osteoarthritis pain, swelling, and
stiffness make it difficult to perform ordinary tasks at work or at home. When the lower body
joints are affected, activities such as walking, climbing stairs and lifting objects become difficult.
Medical costs for adults with osteoarthritis are approximately $2,079 per person per year.3 In
2010, there were 21.7 million ambulatory care visits and over 6.7 million inpatient
hospitalizations for people with OA.3 These statistics demonstrate the importance of providing
pain relief to patients with OA in efforts to decrease health care visits and health care costs.
Long-term management of osteoarthritis requires a multidisciplinary approach, including
the help from physician assistants, to manage symptoms, improve joint mobility and flexibility,
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and maintain a healthy weight. OA can affect any joint, but it occurs most often in knees, hips,
lower back and neck, small joints of the fingers and the bases of the thumb and great toe.4
Several specific risk factors have been identified including obesity and metabolic disease, age,
sex, nutrition, smoking, bone density and muscle function.4 Aside from non-medical treatments
including weight loss, physical therapy, assistive devices, and dietary supplements, there are very
few medications that can be used in the management of this disease due to their association with
multiple side effects. These medications include acetaminophen, NSAIDs, topical NSAIDs,
including capsaicin cream and diclofenac gel, opioids, and joint injections with corticosteroids or
hyaluronic acid. Thus, when lifestyle modifications are ineffective and patients have exhausted
all the recommended medications, their last option is surgery and not all elderly patients are
suitable for that option. Therefore, this paper will be reviewing tanezumab as an alternative
medication. Tanezumab is a humanized monoclonal antibody that targets, binds to, and inhibits
nerve growth factor (NGF).5 NGF increases in the body when there is injury, inflammation or
chronic pain. Tanezumab inhibits the NGF and thereby stops pain signals from reaching the
spinal cord and brain.5 This mechanism is different from that of conventional opioids and
analgesics.5
OBJECTIVE
The objective of this selective EBM review is to determine whether or not tanezumab is
more effective than a placebo in reducing pain in patients with osteoarthritis.
METHODS
Three double-blind randomized clinical trials (RCTs) were selected for this review. These
studies consisted of males and females with hip or knee osteoarthritis pain. The intervention was
tanezumab 10 mg IV, and comparisons were done between the treatment group receiving
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tanezumab and the experimental group who received a comparison drug. The studies measured
the efficacy of tanezumab on reducing knee or hip osteoarthritis pain using the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) pain scale.
All articles were published in peer-reviewed journals between 2012 and 2015, and they
were published in English. Key words used during research via PubMed were “tanezumab,”
“osteoarthritis,” “knee pain,” and “hip pain.” The articles chosen were based on their relevance
to the clinical question and on importance of outcome to the patient (patient oriented evidence
that matters). Inclusion criteria for the studies selected required the use of randomized control
double-blinded trials and studies published after 2006. Exclusion criteria involved the use of
DOE outcome measures. The statistics reported in the selected studies were p-values. Table 1
represents the demographics and characteristics of the included studies.
Table 1- Demographics and Characteristics of Included Studies
Study

Type

# Pts

Brown et
al.5
(2013)

RCT

621

Age
(yrs)
3287

Inclusion Criteria

Exclusion criteria

W/D

Interventions

-Unwillingness/inability to take
nonopiate pain medications,
inadequate pain relief from
nonopiate pain medications, or
candidacy for intraarticular
injections or total hip joint
replacement.
-WOMAC score of ³ 4 at screening
and ³ 5 at baseline, and an increase
of ³ 1 from screening to baseline if
they had been regularly taking pain
medications prior to screening and
were required to wash out prior to
baseline.

-Pregnant or intent to become
pregnant during the study
-BMI >39 kg/m2
-Had moderate to severe pain
other than that related to OA
-Had any condition that could
confound OA pain assessment
-Had significant cardiac,
neurologic, or psychiatric
conditions.

10

tanezumab
10 mg IV
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Brown et
al.6
(2012)

RCT

690

2192

Schnitzer
et al.7

RCT

2700

2093

-X-ray taken within the previous 12
months
-Kellgren-Lawrence X-ray grade ³
2
-At least 1 of the following:
unwillingness or inability to take
nonopiate medications, inadequate
pain relief from nonopiate
medications, candidacy for
intraarticular injections, knee
arthroplasty, or knee replacement
surgery.
-WOMAC score in the index knee
³ 4 at screening and ³ 5 at baseline,
and in patients who washed out of
regularly taken pain medications
after screening, an increase ³ 1
from screening to baseline.
-Kellgren-Lawrence grade ³ 2
-BMI £ 39 kg/m2
-Taking stable oral NSAID
(naproxen 500-1000 mg/day or
celecoxib 200 mg/day for minimum
of 30 days prior to screening, and
experiencing at least some
analgesic benefit
-WOMAC score ³ 4 at screening
-Have at least 70% compliance with
study-supplied oral NSAID
treatment over at least 14 days
directly prior to baseline

4

-Patients who were pregnant or
intended to become pregnant
during the study
-BMI > 39 kg/m2
-Patient who had pain
syndromes that could confound
assessment of pain from OA
(e.g. fibromyalgia, systemic
lupus erythematosus), or had
significant cardiac, neurologic,
or psychological conditions

72

tanezumab
10 mg IV

-“Similar to other tanezumab
trials”
-Any abnormality that would
preclude continued NSAID
therapy, including countryspecific restrictive exclusion
criteria for naproxen or
celecoxib use in subjects with
cardiac disease

376

tanezumab
10 mg IV

OUTCOMES MEASURED
The primary outcome measured in the selected studies were based on pain assessment
before and after treatment with tanezumab or comparison drug using the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) pain scale. All three studies used the
WOMAC pain scale for evaluation of pain at baseline (study day 1) and at week 16. This was
measured using a numerical rating scale of 0 to 10, in which increasing scores represent greater
pain intensity. All three studies provided an adverse event as dichotomous data, reporting the
number of patients in both experimental and comparison groups who experienced paresthesias.
RESULTS
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In the study by Brown et al.5 (2013), efficacy data was based on a modified ITT
population (611 patients), which was defined as all patients who were randomized and treated
with at least 1 dose of study medication, but which excluded all patients from 1 study site
because of significant deviations from good clinical practice and 1 additional patient from
another site due to possible unblinding.5 Patients were randomized equally to receive intravenous
tanezumab 10 mg or a comparison drug. For both groups, study medication was administered at
8-week intervals, and efficacy data was measured at baseline and at week 16. Patient
demographics and baseline characteristics were similar across treatment groups, as shown above
in Table 1.
At the conclusion of the study, the WOMAC pain scale changed from baseline to week
16, producing statistically significant improvements (p ≤0.001) relative to the comparison. At the
start of the study (study day 1), both the experimental group and comparison group had an
average WOMAC pain scale score of 7.3. By week 16, the mean change from baseline was -1.62
for the comparison group and -3.37 for the experimental group, producing a p-value of ≤0.001
for the experimental group. This is demonstrated below in Table 2.
Table 2 – Statistical outcome measures for patients with osteoarthritic hip pain

Comparison
Tanezumab

Outcome
measured

Scoring
system

Baseline

Mean change
from baseline

Pain
Pain

WOMAC
WOMAC

7.3
7.3

-1.62
-3.37

P-value
≤0.001

In this study safety data was based on the ITT population, which was defined as all
patients who were randomized and treated with at least 1 dose of study medication.5 Brown et
al.5 (2013) demonstrated that 5.1% of the patients in the experimental group experienced
paresthesias while 3.9% in the comparison group. This correlates with a NNH of 83, concluding
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that for every 83 people treated with tanezumab, 1 more person will experience paresthesias
when compared to the control (Table 5 below).
In the study by Brown et al.6 (2012), 690 individuals (ITT population) received study
medication, however a modified intent-to-treat (mITT) population of 618 was established. mITT
population was defined as all patients randomized and treated with ≥ 1 dose of study medication
and excluding patients from any study site that was found to have significant deviation from
good clinical practices or patients from whom there were possible breaches in study blinding. 6
Results from analyses performed using the ITT population were consistent with those obtained
using the mITT population and led to the same conclusions.6 Patients received blinded study
medication at 8 week intervals on 3 occasions: baseline (study day 1), week 8 (study day 57),
and week 16 (study day 113). Primary efficacy results were measured at week 16.
At the completion of this study, treatment with tanezumab produced significant
improvement in pain from baseline to week 16 in primary efficacy measures. Baseline scores for
the comparison group and experimental group were 7.1 and 7.0 respectively. The mean change
from baseline in the comparison group was approximately -2.5, and in the experimental group it
was approximately -3.5, based on the graphical data provided in the study (Table 3). Treatment
with tanezumab had a significant improvement in the primary WOMAC pain scale compared to
the control with a p-value of ≤0.001.
Table 3 - Statistical outcome measures for patients with osteoarthritic knee pain

Comparison
Tanezumab

Outcome
measured

Scoring
system

Baseline

Mean change
from baseline

Pain
Pain

WOMAC
WOMAC

7.1
7.0

-2.5
-3.5

P-value
≤0.001
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Brown et al.6 (2012) provided dichotomous data to calculate NNH on the adverse event
of paresthesias due to the treatment. The study demonstrated that 5.1% of the patients in the
experimental group experienced adverse events while 1.7% in the comparison group. This
correlates with a NNH of 29, concluding that for every 29 people treated with tanezumab, 1 more
person will experience an adverse event when compared to control (Table 5 below).
In the study by Schnitzer et al.7, participants were randomized by a computer-generated
randomization code to either the tanezumab group or the comparison group. Tanezumab or
matching comparison was given intravenously at baseline and every 8 weeks for a total of 7
administrations. Efficacy and safety were assessed using ITT populations and results were
measured on week 16.
At the completion of this study, it was determined that at the 16-week mark tanezumab
resulted in significant greater mean improvement of WOMAC pain compared to the comparison
drug with a p-value of ≤0.001. The baseline score for both groups was 6.3, with the mean change
from baseline being -1.5 for the comparison group and -2.25 for the experimental group. This
correlates with a p-value ≤0.001 for the experimental group versus the comparison group.
Table 4 - Statistical outcome measures for patients with osteoarthritic knee and hip pain

Comparison
Tanezumab

Outcome
measured

Scoring
system

Baseline

Mean change
from baseline

Pain
Pain

WOMAC
WOMAC

6.3
6.3

-1.5
-2.25

P-value
≤0.001

Schnitzer et al.7 demonstrated that 7.2% of the patients in the experimental group
experienced an adverse event while 3.1% in the control group. This correlates to a NNH of 24,
concluding that for every 24 people being treated with tanezumab, 1 more person will experience
an adverse event of paresthesias when compared to control (Table 5).
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Table 5 – Statistical data on the adverse event in each study
AE: Paresthesias

Control
event rate
(%)

Experimental
event rate
(%)
5.1

Relative
risk
increase
(RRI)
0.31

Absolute
risk
increase
(ARI)
0.012

Number
needed to
harm
(NNH)
83 patients

Brown et al.5 (2013)

3.9

Brown et al.6 (2012)

1.7

5.1

2

0.034

29 patients

Schnitzer et al.7

3.1

7.2

1.3

0.041

24 patients

DISCUSSION
The results above demonstrate a benefit to the use of tanezumab in patients with knee or
hip osteoarthritis pain. The p-value for the treatment of tanezumab in all three studies are ≤0.001
indicating that there is significant improvement in pain after using tanezumab. The NNH for
Brown et al.5 (2013), Brown et al.6 (2012) and Schnitzer et al.7 are 83, 29 and 24 respectively,
indicating that a large number of people can be treated with tanezumab before the adverse event
of paresthesias occur (Table 5). Even so, the adverse events reported were not consistent with
progressively worsening peripheral nerve damage with tanezumab treatment leading to
peripheral polyneuropathy. Evidence from neurologic evaluations of patients reporting adverse
events revealed symptoms were associated with focal mononeuropathy, such as carpal tunnel
syndrome, that was preexisting or possibly aggravated by tanezumab treatment.5,6,7
There is a limitation noted in the study by Schnitzer et al.7 that should be discussed.
During this study, the FDA placed all clinical studies of tanezumab on clinical hold due to
unexpected adverse events initially described as osteonecrosis that required total joint
replacement. The primary efficacy objectives of this study were not impacted by the clinical
hold, however assessment of long-term efficacy (beyond 16 weeks) was limited.7
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It is important to mention that the title of this systemic review is incorrect. The word
“placebo” was used in the title of this review when in fact tanezumab has been compared to both
placebos and an NSAID in the RCTs selected for this review. In the studies by Brown et al.
(2012 and 2013) the efficacy of tanezumab for reducing pain is compared to placebos. In the
study by Schnitzer et al. the efficacy of tanezumab for reducing pain is compared to Naproxen.
Therefore, the title of this review is incorrect and must be corrected and generalized so it states
that tanezumab has been compared to comparison drugs.
CONCLUSION
The results of this systematic review suggest that tanezumab is more effective than
comparison drugs in reducing pain in patients with osteoarthritis of the knee or hip. The p-value
in each study revealed statistical significance in the use of tanezumab when compared to the
comparison drugs, and the NNH calculated in each study demonstrated little adverse events.
However, paresthesias can be relatively bothersome to live with as an adverse event from
treatment with tanezumab. Therefore, future study populations should consist of patients with
little to no medical histories that could predispose those patients to findings suggestive of
neuropathy during the study. This could help determine if the adverse event of paresthesias is
related to treatment with tanezumab.
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